Literature DB >> 1872902

Broad-spectrum anti-DNA virus and anti-retrovirus activity of phosphonylmethoxyalkylpurines and -pyrimidines.

E De Clercq1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1872902     DOI： 10.1016/0006-2952(91)90276-b

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN： 0006-2952            Impact factor:   5.858


× No keyword cloud information.
  24 in total

1.  Activity of different antiviral drug combinations against human cytomegalovirus replication in vitro.

Authors:  R Snoeck; G Andrei; D Schols; J Balzarini; E De Clercq
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-12       Impact factor: 3.267

2.  MDL 74,968, a new acyclonucleotide analog: activity against human immunodeficiency virus in vitro and in the hu-PBL-SCID.beige mouse model of infection.

Authors:  C G Bridges; D L Taylor; P S Ahmed; T M Brennan; J M Hornsperger; J F Navé; P Casara; A S Tyms
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

3.  Disposition of the acyclic nucleoside phosphonate (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine.

Authors:  M K Bijsterbosch; L J Smeijsters; T J van Berkel
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

4.  Antiviral efficacy and pharmacokinetics of oral adefovir dipivoxil in chronically woodchuck hepatitis virus-infected woodchucks.

Authors:  J M Cullen; D H Li; C Brown; E J Eisenberg; K C Cundy; J Wolfe; J Toole; C Gibbs
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

5.  Interaction of the human adenovirus proteinase with its 11-amino acid cofactor pVIc.

Authors:  M L Baniecki; W J McGrath; S M McWhirter; C Li; D L Toledo; P Pellicena; D L Barnard; K S Thorn; W F Mangel
Journal:  Biochemistry       Date:  2001-10-16       Impact factor: 3.162

Review 6.  Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives.

Authors:  J Balzarini
Journal:  Pharm World Sci       Date:  1994-04-15

Review 7.  Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections.

Authors:  Erik De Clercq
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

8.  Antischistosomal activity of hexadecyloxypropyl cyclic 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine and other alkoxyalkyl esters of acyclic nucleoside phosphonates assessed by schistosome worm killing in vitro.

Authors:  Sanaa S Botros; Samia William; James R Beadle; Nadejda Valiaeva; Karl Y Hostetler
Journal:  Antimicrob Agents Chemother       Date:  2009-08-24       Impact factor: 5.191

9.  Susceptibilities of zidovudine-resistant variants of human immunodeficiency virus type 1 to inhibition by acyclic nucleoside phosphonates.

Authors:  Y F Gong; D R Marshall; R V Srinivas; A Fridland
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

10.  Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients.

Authors:  K C Cundy; P Barditch-Crovo; R E Walker; A C Collier; D Ebeling; J Toole; H S Jaffe
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.